View in EDS HTML Full Text PDF Full Text

Disability progression in multiple sclerosis patients using early first‐line treatments.

Saved in:
Bibliographic Details
Title: Disability progression in multiple sclerosis patients using early first‐line treatments.
Authors: Lefort, Mathilde (AUTHOR), Vukusic, Sandra (AUTHOR), Casey, Romain (AUTHOR), Edan, Gilles (AUTHOR), Leray, Emmanuelle (AUTHOR), Cotton, François (AUTHOR), De Sèze, Jérôme (AUTHOR), Douek, Pascal (AUTHOR), Guillemin, Francis (AUTHOR), Laplaud, David (AUTHOR), Lebrun‐Frenay, Christine (AUTHOR), Pachot, Alexandre (AUTHOR), Moreau, Thibault (AUTHOR), Olaiz, Javier (AUTHOR), Pelletier, Jean (AUTHOR), Rigaud‐Bully, Claire (AUTHOR), Stankoff, Bruno (AUTHOR), Zephir, Hélène (AUTHOR), Marignier, Romain (AUTHOR), Debouverie, Marc (AUTHOR)
Source: European Journal of Neurology. Sep2022, Vol. 29 Issue 9, p2761-2771. 11p.
Subjects: Multiple sclerosis, Glatiramer acetate, Disabilities, Older patients, Treatment delay (Medicine), People with disabilities
Abstract: Background and purpose: Therapeutic management of relapsing–remitting multiple sclerosis (RRMS) has evolved towards early treatment. The objective was to assess the impact of early treatment initiation on disability progression amongst RRMS first‐line‐treated patients. Methods: This study included all incident RRMS cases starting interferon or glatiramer acetate for the first time from 1 January 1996 to 31 December 2012 (N = 5279) from 10 MS expert Observatoire Français de la Sclérose en Plaques centres. The delay from treatment start to attaining an irreversible Expanded Disability Status Scale (EDSS) score of 3.0 was compared between the early group (N = 1882; treated within 12 months following MS clinical onset) and the later group using propensity score weighted Kaplan–Meier methods, overall and stratified by age. Results: Overall, the restricted mean time before reaching EDSS 3.0 from treatment start was 11 years and 2 months for patients treated within the year following MS clinical onset and 10 years and 7 months for patients treated later. Thus, early treated patients gained 7 months (95% confidence interval [CI] 4–11 months) in the time to reach EDSS 3.0 compared to patients treated later (treatment start delayed by 28 months). The difference in restricted mean time was respectively 6 months (95% CI 1–10 months) and 14 months (95% CI 4–24 months) in the ≤40 years age group and in the >40 years age group, in favour of the early group. Conclusions: Early treatment initiation resulted in a significant reduction of disability progression amongst patients with RRMS, and also amongst older patients. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 158392255
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Disability progression in multiple sclerosis patients using early first‐line treatments.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Lefort%2C+Mathilde%22">Lefort, Mathilde</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vukusic%2C+Sandra%22">Vukusic, Sandra</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Casey%2C+Romain%22">Casey, Romain</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Edan%2C+Gilles%22">Edan, Gilles</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leray%2C+Emmanuelle%22">Leray, Emmanuelle</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cotton%2C+François%22">Cotton, François</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Sèze%2C+Jérôme%22">De Sèze, Jérôme</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Douek%2C+Pascal%22">Douek, Pascal</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Guillemin%2C+Francis%22">Guillemin, Francis</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Laplaud%2C+David%22">Laplaud, David</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lebrun‐Frenay%2C+Christine%22">Lebrun‐Frenay, Christine</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pachot%2C+Alexandre%22">Pachot, Alexandre</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moreau%2C+Thibault%22">Moreau, Thibault</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Olaiz%2C+Javier%22">Olaiz, Javier</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pelletier%2C+Jean%22">Pelletier, Jean</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rigaud‐Bully%2C+Claire%22">Rigaud‐Bully, Claire</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stankoff%2C+Bruno%22">Stankoff, Bruno</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zephir%2C+Hélène%22">Zephir, Hélène</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marignier%2C+Romain%22">Marignier, Romain</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Debouverie%2C+Marc%22">Debouverie, Marc</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Neurology%22">European Journal of Neurology</searchLink>. Sep2022, Vol. 29 Issue 9, p2761-2771. 11p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Multiple+sclerosis%22">Multiple sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Glatiramer+acetate%22">Glatiramer acetate</searchLink><br /><searchLink fieldCode="DE" term="%22Disabilities%22">Disabilities</searchLink><br /><searchLink fieldCode="DE" term="%22Older+patients%22">Older patients</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+delay+%28Medicine%29%22">Treatment delay (Medicine)</searchLink><br /><searchLink fieldCode="DE" term="%22People+with+disabilities%22">People with disabilities</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and purpose: Therapeutic management of relapsing–remitting multiple sclerosis (RRMS) has evolved towards early treatment. The objective was to assess the impact of early treatment initiation on disability progression amongst RRMS first‐line‐treated patients. Methods: This study included all incident RRMS cases starting interferon or glatiramer acetate for the first time from 1 January 1996 to 31 December 2012 (N = 5279) from 10 MS expert Observatoire Français de la Sclérose en Plaques centres. The delay from treatment start to attaining an irreversible Expanded Disability Status Scale (EDSS) score of 3.0 was compared between the early group (N = 1882; treated within 12 months following MS clinical onset) and the later group using propensity score weighted Kaplan–Meier methods, overall and stratified by age. Results: Overall, the restricted mean time before reaching EDSS 3.0 from treatment start was 11 years and 2 months for patients treated within the year following MS clinical onset and 10 years and 7 months for patients treated later. Thus, early treated patients gained 7 months (95% confidence interval [CI] 4–11 months) in the time to reach EDSS 3.0 compared to patients treated later (treatment start delayed by 28 months). The difference in restricted mean time was respectively 6 months (95% CI 1–10 months) and 14 months (95% CI 4–24 months) in the ≤40 years age group and in the >40 years age group, in favour of the early group. Conclusions: Early treatment initiation resulted in a significant reduction of disability progression amongst patients with RRMS, and also amongst older patients. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=158392255
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ene.15422
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 2761
    Subjects:
      – SubjectFull: Multiple sclerosis
        Type: general
      – SubjectFull: Glatiramer acetate
        Type: general
      – SubjectFull: Disabilities
        Type: general
      – SubjectFull: Older patients
        Type: general
      – SubjectFull: Treatment delay (Medicine)
        Type: general
      – SubjectFull: People with disabilities
        Type: general
    Titles:
      – TitleFull: Disability progression in multiple sclerosis patients using early first‐line treatments.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lefort, Mathilde
      – PersonEntity:
          Name:
            NameFull: Vukusic, Sandra
      – PersonEntity:
          Name:
            NameFull: Casey, Romain
      – PersonEntity:
          Name:
            NameFull: Edan, Gilles
      – PersonEntity:
          Name:
            NameFull: Leray, Emmanuelle
      – PersonEntity:
          Name:
            NameFull: Cotton, François
      – PersonEntity:
          Name:
            NameFull: De Sèze, Jérôme
      – PersonEntity:
          Name:
            NameFull: Douek, Pascal
      – PersonEntity:
          Name:
            NameFull: Guillemin, Francis
      – PersonEntity:
          Name:
            NameFull: Laplaud, David
      – PersonEntity:
          Name:
            NameFull: Lebrun‐Frenay, Christine
      – PersonEntity:
          Name:
            NameFull: Pachot, Alexandre
      – PersonEntity:
          Name:
            NameFull: Moreau, Thibault
      – PersonEntity:
          Name:
            NameFull: Olaiz, Javier
      – PersonEntity:
          Name:
            NameFull: Pelletier, Jean
      – PersonEntity:
          Name:
            NameFull: Rigaud‐Bully, Claire
      – PersonEntity:
          Name:
            NameFull: Stankoff, Bruno
      – PersonEntity:
          Name:
            NameFull: Zephir, Hélène
      – PersonEntity:
          Name:
            NameFull: Marignier, Romain
      – PersonEntity:
          Name:
            NameFull: Debouverie, Marc
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: Sep2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 13515101
          Numbering:
            – Type: volume
              Value: 29
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: European Journal of Neurology
              Type: main
ResultId 1